Pathstone Family Office’s Amicus Therapeutics FOLD Stock Holding History

Pathstone Family Office’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.25M	Buy	103,177 +289	+0.3%	+$3.73K	0.01%	622
2023 Q2	$1.29M	Hold	102,888	–	–	0.02%	408
2023 Q1	$1.14M	Sell	102,888 -102,552	-50%	-$1.26M	0.02%	412
2022 Q4	$2.51M	Buy	205,440 +1,618	+0.8%	+$18.2K	0.02%	434
2022 Q3	$2.13M	Buy	203,822 +101,911	+100%	+$1.14M	0.02%	421
2022 Q2	$1.09M	Buy	+101,911	New	+$839K	0.02%	322
2020 Q3	–	Sell	-4,000	Closed	-$60K	–	869
2020 Q2	$60K	Hold	4,000	–	–	0.01%	292
2020 Q1	$37K	Buy	+4,000	New	+$38K	0.01%	347

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Pathstone Family Office's FOLD Position: Q3 2023 in Review

Pathstone Family Office increased its Amicus Therapeutics (FOLD) stake by 0.28% in Q3 2023, buying an estimated $3.73K and bringing the position to 103,177 shares worth $1.25M. The position accounts for 0.01% of the portfolio, ranked #622.

Pathstone Family Office first reported a position in FOLD in Q1 2020 and has held it in 8 quarters since. The position peaked at $2.51M in Q4 2022. 228 funds tracked by Wall St. Rank hold FOLD as of Q3 2023.

Pathstone Family Office held 103,177 shares of Amicus Therapeutics worth $1.25M as of Q3 2023.
Pathstone Family Office bought 289 Amicus Therapeutics shares in Q3 2023, an estimated $3.73K.
Amicus Therapeutics made up 0.01% of Pathstone Family Office's portfolio in Q3 2023, its #622 holding.
Pathstone Family Office first reported a position in Amicus Therapeutics in Q1 2020 and has held it in 8 quarters since.
Pathstone Family Office's Amicus Therapeutics position peaked at $2.51M in Q4 2022.
228 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.